IMvigor211, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of atezolizumab versus chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen

        Z

NCT02302807    



Studied treatment atezolizumab
Control treatment chemotherapy



Patients patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen
Size932



Blindness open label Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint overall survival Design Parallel groups



EndpointX1N1X0N0TE95% CI0,22,01,0

negative results (press realease)

Links

Press release

ClinicalTrial.gov record NCT02302807



Registering number NCT02302807 (see trial on clinicaltrials.gov)
Code Name

Comment: The sponsor has revealed that its phase III IMVigor 211 failed to meet the primary endpoint of extending overall survival compared with chemotherapy,